SEC Form 4 · accession 0001140361-18-011289

Emergent BioSolutions Inc. · EBS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, Chief HR Officer

Period of report

Feb 27, 2018

Accepted (ET)

Mar 1, 2018 · 5:05 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001367644

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2	Feb 27, 2018	A	4,029	$0.00	A	13,969	D
Common Stock^F3	Feb 27, 2018	A	4,029	$0.00	A	17,998	D
Common Stock^F1	Feb 27, 2018	F	387	$49.64	D	17,611	D
Common Stock^F1	Feb 28, 2018	F	540	$49.97	D	17,071	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F4	$49.64	Feb 27, 2018	A	16,116	A	—	Feb 26, 2025	Common Stock	16,116	16,116	D

F1Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
F2These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F3Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period.
F4Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021.